Antibodies and antibody-derived macromolecules have established themselves as the
mainstay in protein-based therapeutic molecules (biologics). Our knowledge of the structure …

Bispecific antibodies (bsAbs) enable novel mechanisms of action and/or therapeutic
applications that cannot be achieved using conventional IgG-based antibodies …

Bispecific antibodies (bsAb) that target two independent epitopes or antigens have been
extensively explored in translational and clinical studies since they were first developed in …

Simple Summary CD3-bispecific antibody therapy is a form of immunotherapy that enables
soldier cells of the immune system to recognize and kill tumor cells. This type of therapy is …

Bispecific antibodies (bsAbs) bind two different epitopes on the same or different antigens.
Through this dual specificity for soluble or cell-surface antigens, bsAbs exert activities …

The concepts for T-cell redirecting bispecific antibodies (TRBAs) and chimeric antigen
receptor (CAR)-T cells are both at least 30 years old but both platforms are just now coming …

Bispecific antibodies (BsAbs) are designed to recognize and bind to two different antigens or
epitopes. In the last few decades, BsAbs have been developed within the context of cancer …

T cell engagers (TCEs) are targeted immunotherapies that have emerged as a promising
treatment to redirect effector T cells for tumor cell killing. The strong therapeutic value of …

The development of bispecific antibodies that redirect the cytotoxic activity of CD3+ T cells to
tumours is a promising immunotherapeutic strategy for the treatment of haematological …

T cell-based immunotherapy has revolutionized oncological treatment. However, many
patients do not respond to treatment, and long-term remissions remain rare, particularly in …